[Skip to Content]
[Skip to Content Landing]

Neonatal Abstinence SyndromeAdvances in Diagnosis and Treatment

Educational Objective
To review the clinical management of infants with neonatal abstinence syndrome.
1 Credit CME
Key Points

Question  What are the recent advances in the diagnosis and treatment of neonatal abstinence syndrome?

Findings  Novel methods are being developed to assess and diagnose neonatal abstinence syndrome objectively, but none are routinely used in clinical practice. Nonpharmacologic interventions may decrease the need for pharmacologic treatment; however, there are no high-quality randomized clinical trials to support these nonpharmacologic interventions, and there are few randomized studies with prespecified sample size calculations to support pharmacologic treatment regimens. Data concerning neurodevelopmental outcomes are limited.

Meaning  Nonpharmacologic interventions represent the most substantial changes in the treatment of neonatal abstinence syndrome. High-quality randomized studies are necessary to demonstrate the effectiveness of new diagnostic approaches and pharmacologic and nonpharmacologic interventions.

Abstract

Importance  Neonatal abstinence syndrome, which occurs as a result of in utero opioid exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial variability in how neonatal abstinence syndrome is diagnosed and managed.

Objective  To summarize key studies examining the diagnosis and management (both pharmacologic and nonpharmacologic) of neonatal abstinence syndrome published during the past 10 years.

Evidence Review  PubMed, Web of Science, and CINAHL were searched for articles published between July 1, 2007, and December 31, 2017. Abstracts were screened and included in the review if they pertained to neonatal abstinence syndrome diagnosis or management and were judged by the authors to be clinical trials, cohort studies, or case series.

Findings  A total of 53 articles were included in the review, including 9 randomized clinical trials, 35 cohort studies, 1 cross-sectional study, and 8 case series—representing a total of 11 905 unique opioid-exposed mother-infant dyads. Thirteen studies were identified that evaluated established or novel neonatal abstinence syndrome assessment methods, such as brief neonatal abstinence syndrome assessment scales or novel objective physiologic measures to predict withdrawal. None of the new techniques that measure infant physiologic parameters are routinely used in clinical practice. The most substantial number of studies of neonatal abstinence syndrome management pertain to nonpharmacologic care—specifically, interventions that promote breastfeeding or encourage parents to room-in with their newborns. Although these nonpharmacologic interventions appear to decrease the need for pharmacologic treatment and result in shorter hospitalizations, the interventions are heterogeneous and there are no high-quality clinical trials to support them. Regarding pharmacologic interventions, only 5 randomized clinical trials with prespecified sample size calculations (4 infant, 1 maternal treatment) have been published. Each of these trials was small (from 26 to 131 participants) and tested different therapies, limiting the extent to which results can be aggregated. There is insufficient evidence to support an association between any diagnostic or treatment approach and differential neurodevelopmental outcomes among infants with neonatal abstinence syndrome.

Conclusions and Relevance  Evidence pertaining to the optimal diagnosis and treatment strategies for neonatal abstinence syndrome is based on small or low-quality studies that focus on intermediate outcomes, such as need for pharmacologic treatment or length of hospital stay. Clinical trials are needed to evaluate health and neurodevelopmental outcomes associated with objective diagnostic approaches as well as pharmacologic and nonpharmacologic treatment modalities.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Elisha M. Wachman, MD, Boston Medical Center, 771 Albany St, Dowling 4103, Boston, MA 02118 (elisha.wachman@bmc.org).

Accepted for Publication: February 23, 2018.

Author Contributions: Drs Wachman and Schiff had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Additional Contributions: We acknowledge Hira Shrestha, MA, and Ryham Saleh, BA, from Boston Medical Center, and Zoe Thomas from the University of Massachusetts for their assistance with the literature search for this article. They received no compensation for their contributions.

References
1.
Jansson  LM, Velez  M, Harrow  C.  The opioid-exposed newborn: assessment and pharmacologic management.  J Opioid Manag. 2009;5(1):47-55.PubMedGoogle ScholarCrossref
2.
Hudak  ML, Tan  RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics.  Neonatal drug withdrawal.  Pediatrics. 2012;129(2):e540-e560. doi:10.1542/peds.2011-3212PubMedGoogle ScholarCrossref
3.
Patrick  SW, Davis  MM, Lehman  CU, Cooper  WO.  Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012.  J Perinatol. 2015;35(8):667. doi:10.1038/jp.2015.63PubMedGoogle ScholarCrossref
4.
Ko  JY, Patrick  SW, Tong  VT, Patel  R, Lind  JN, Barfield  WD.  Incidence of neonatal abstinence syndrome—28 states, 1999-2013.  MMWR Morb Mortal Wkly Rep. 2016;65(31):799-802. doi:10.15585/mmwr.mm6531a2PubMedGoogle ScholarCrossref
5.
Bogen  DL, Whalen  BL, Kair  LR, Vining  M, King  BA.  Wide variation found in care of opioid-exposed newborns.  Acad Pediatr. 2017;17(4):374-380. doi:10.1016/j.acap.2016.10.003PubMedGoogle ScholarCrossref
6.
Milliren  CE, Gupta  M, Graham  DA, Melvin  P, Jorina  M, Ozonoff  A.  Hospital variation in neonatal abstinence syndrome incidence, treatment modalities, resource use, and costs across pediatric hospitals in the United States, 2013 to 2016.  Hosp Pediatr. 2018;8(1):15-20.PubMedGoogle ScholarCrossref
7.
Oei  JL, Melhuish  E, Uebel  H,  et al.  Neonatal abstinence syndrome and high school performance.  Pediatrics. 2017;139(2):e20162651. doi:10.1542/peds.2016-2651PubMedGoogle ScholarCrossref
8.
Nygaard  E, Moe  V, Slinning  K, Walhovd  KB.  Longitudinal cognitive development of children born to mothers with opioid and polysubstance use.  Pediatr Res. 2015;78(3):330-335. doi:10.1038/pr.2015.95PubMedGoogle ScholarCrossref
9.
Konijnenberg  C, Melinder  A.  Executive function in preschool children prenatally exposed to methadone or buprenorphine.  Child Neuropsychol. 2015;21(5):570-585. doi:10.1080/09297049.2014.967201PubMedGoogle ScholarCrossref
10.
Finnegan  LP, Connaughton  JF  Jr, Kron  RE, Emich  JP.  Neonatal abstinence syndrome: assessment and management.  Addict Dis. 1975;2(1-2):141-158.PubMedGoogle Scholar
11.
Grossman  M, Seashore  C, Holmes  AV.  Neonatal abstinence syndrome management: a review of recent evidence.  Rev Recent Clin Trials. 2017;12(4):226-232. doi:10.2174/1574887112666170816144818PubMedGoogle ScholarCrossref
12.
McQueen  K, Murphy-Oikonen  J.  Neonatal abstinence syndrome.  N Engl J Med. 2016;375(25):2468-2479. doi:10.1056/NEJMra1600879PubMedGoogle ScholarCrossref
13.
Klaman  SL, Isaacs  K, Leopold  A,  et al.  Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance.  J Addict Med. 2017;11(3):178-190. doi:10.1097/ADM.0000000000000308PubMedGoogle ScholarCrossref
14.
Howick  J, Chalmers  I,  et al; Oxford Centre for Evidence-Based Medicine. Levels of Evidence. https://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf. Accessed March 3, 2018.
15.
Kistin  C, Silverstein  M.  Pilot studies: a critical but potentially misused component of interventional research.  JAMA. 2015;314(15):1561-1562. doi:10.1001/jama.2015.10962PubMedGoogle ScholarCrossref
16.
Dekkers  OM, Egger  M, Altman  DG, Vandenbroucke  JP.  Distinguishing case series from cohort studies.  Ann Intern Med. 2012;156(1 pt 1):37. doi:10.7326/0003-4819-156-1-201201030-00006.Google ScholarCrossref
17.
Maguire  D, Cline  GJ, Parnell  L, Tai  C-Y.  Validation of the Finnegan neonatal abstinence syndrome tool-short form.  Adv Neonatal Care. 2013;13(6):430-437. doi:10.1097/ANC.0000000000000033PubMedGoogle ScholarCrossref
18.
Nagiub  M, Alton  K, Avula  V, Hagglund  K, Anne  P.  Heart rate variability evaluation in the assessment and management of in-utero drug-exposed infants.  SAGE Open Med. 2014;2:2050312114556525. doi:10.1177/2050312114556525PubMedGoogle ScholarCrossref
19.
Jones  HE, Seashore  C, Johnson  E,  et al.  Psychometric assessment of the Neonatal Abstinence Scoring System and the MOTHER NAS Scale.  Am J Addict. 2016;25(5):370-373. doi:10.1111/ajad.12388PubMedGoogle ScholarCrossref
20.
Jansson  LM, Dipietro  JA, Elko  A, Velez  M.  Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates.  J Matern Fetal Neonatal Med. 2007;20(9):677-685. doi:10.1080/14767050701490327PubMedGoogle ScholarCrossref
21.
Leeman  LM, Brown  SA, Albright  B, Skipper  B, Hsi  A, Rayburn  WF.  Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates.  J Matern Fetal Neonatal Med. 2011;24(7):955-959. doi:10.3109/14767058.2010.536863PubMedGoogle ScholarCrossref
22.
Chisamore  B, Labana  S, Blitz  S, Ordean  A.  A comparison of morphine delivery in neonatal opioid withdrawal.  Subst Abuse. 2016;10(suppl 1):49-54. doi:10.4137/SART.S34550PubMedGoogle Scholar
23.
Jones  HE, Seashore  C, Johnson  E, Horton  E, O’Grady  KE, Andringa  K.  Measurement of neonatal abstinence syndrome: evaluation of short forms.  J Opioid Manag. 2016;12(1):19-23. doi:10.5055/jom.2016.0308PubMedGoogle ScholarCrossref
24.
Oji-Mmuo  CN, Michael  EJ, McLatchy  J, Lewis  MM, Becker  JE, Doheny  KK.  Skin conductance at baseline and postheel lance reflects sympathetic activation in neonatal opiate withdrawal.  Acta Paediatr. 2016;105(3):e99-e106. doi:10.1111/apa.13287PubMedGoogle ScholarCrossref
25.
Grossman  MR, Berkwitt  AK, Osborn  RR,  et al.  An initiative to improve the quality of care of infants with neonatal abstinence syndrome.  Pediatrics. 2017;139(6):e20163360. doi:10.1542/peds.2016-3360PubMedGoogle ScholarCrossref
26.
Isemann  BT, Stoeckle  EC, Taleghani  AA, Mueller  EW.  Early prediction tool to identify the need for pharmacotherapy in infants at risk of neonatal abstinence syndrome.  Pharmacotherapy. 2017;37(7):840-848. doi:10.1002/phar.1948PubMedGoogle ScholarCrossref
27.
Oji-Mmuo  CN, Gardner  FC, Doheny  KK.  Heightened sympathetic arousal is demonstrated by skin conductance responsivity to auditory stimuli in a small cohort of neonates with opiate withdrawpal  [published online June 15, 2017].  Brain Res Bull. doi:10.1016/j.brainresbull.2017.06.007PubMedGoogle Scholar
28.
Subedi  L, Huang  H, Pant  A,  et al.  Plasma brain-derived neurotrophic factor levels in newborn infants with neonatal abstinence syndrome.  Front Pediatr. 2017;5:238. doi:10.3389/fped.2017.00238PubMedGoogle ScholarCrossref
29.
Grossman  MR, Lipshaw  MJ, Osborn  RR, Berkwitt  AK.  A novel approach to assessing infants with neonatal abstinence syndrome.  Hosp Pediatr. 2018;8(1):1-6. doi:10.1542/hpeds.2017-0128PubMedGoogle ScholarCrossref
30.
Jones  HE, Kaltenbach  K, Heil  SH,  et al.  Neonatal abstinence syndrome after methadone or buprenorphine exposure.  N Engl J Med. 2010;363(24):2320-2331. doi:10.1056/NEJMoa1005359PubMedGoogle ScholarCrossref
31.
Abrahams  RR, Kelly  SA, Payne  S, Thiessen  PN, Mackintosh  J, Janssen  PA.  Rooming-in compared with standard care for newborns of mothers using methadone or heroin.  Can Fam Physician. 2007;53(10):1722-1730.PubMedGoogle Scholar
32.
Abrahams  RR, MacKay-Dunn  MH, Nevmerjitskaia  V, MacRae  GS, Payne  SP, Hodgson  ZG.  An evaluation of rooming-in among substance-exposed newborns in British Columbia.  J Obstet Gynaecol Can. 2010;32(9):866-871.PubMedGoogle ScholarCrossref
33.
Saiki  T, Lee  S, Hannam  S, Greenough  A.  Neonatal abstinence syndrome: postnatal ward versus neonatal unit management.  Eur J Pediatr. 2010;169(1):95-98. doi:10.1007/s00431-009-0994-0PubMedGoogle ScholarCrossref
34.
Hünseler  C, Brückle  M, Roth  B, Kribs  A.  Neonatal opiate withdrawal and rooming-in: a retrospective analysis of a single center experience.  Klin Padiatr. 2013;225(5):247-251. doi:10.1055/s-0033-1347190PubMedGoogle ScholarCrossref
35.
Newman  A, Davies  GA, Dow  K,  et al.  Rooming-in care for infants of opioid-dependent mothers: implementation and evaluation at a tertiary care hospital.  Can Fam Physician. 2015;61(12):e555-e561.PubMedGoogle Scholar
36.
Holmes  AV, Atwood  EC, Whalen  B,  et al.  Rooming-in to treat neonatal abstinence syndrome: improved family-centered care at lower cost.  Pediatrics. 2016;137(6):e20152929. doi:10.1542/peds.2015-2929PubMedGoogle ScholarCrossref
37.
Howard  MB, Schiff  DM, Penwill  N,  et al.  Impact of parental presence at infants’ bedside on neonatal abstinence syndrome.  Hosp Pediatr. 2017;7(2):63-69. doi:10.1542/hpeds.2016-0147PubMedGoogle Scholar
38.
Dryden  C, Young  D, Hepburn  M, Mactier  H.  Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources.  BJOG. 2009;116(5):665-671. doi:10.1111/j.1471-0528.2008.02073.xPubMedGoogle ScholarCrossref
39.
Isemann  B, Meinzen-Derr  J, Akinbi  H.  Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome.  J Perinatol. 2011;31(1):25-29. doi:10.1038/jp.2010.66PubMedGoogle ScholarCrossref
40.
Pritham  UA, Paul  JA, Hayes  MJ.  Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.  J Obstet Gynecol neonatal Nurs JOGNN. 2012;41(2):180-190. doi:10.1111/j.1552-6909.2011.01330.x.Google ScholarCrossref
41.
O’Connor  AB, Collett  A, Alto  WA, O’Brien  LM.  Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy.  J Midwifery Womens Health. 2013;58(4):383-388. doi:10.1111/jmwh.12009PubMedGoogle ScholarCrossref
42.
Wachman  EM, Hayes  MJ, Brown  MS,  et al.  Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome.  JAMA. 2013;309(17):1821-1827. doi:10.1001/jama.2013.3411PubMedGoogle ScholarCrossref
43.
Welle-Strand  GK, Skurtveit  S, Jansson  LM, Bakstad  B, Bjarkø  L, Ravndal  E.  Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants.  Acta Paediatr. 2013;102(11):1060-1066. doi:10.1111/apa.12378PubMedGoogle Scholar
44.
Short  VL, Gannon  M, Abatemarco  DJ.  The association between breastfeeding and length of hospital stay among infants diagnosed with neonatal abstinence syndrome: a population-based study of in-hospital births.  Breastfeed Med. 2016;11:343-349. doi:10.1089/bfm.2016.0084PubMedGoogle ScholarCrossref
45.
Crook  K, Brandon  D. Prenatal breastfeeding education: impact on infants with neonatal abstinence syndrome.  Adv Neonatal Care. 2017;17(4):299-305. doi:10.1097/ANC.0000000000000392Google ScholarCrossref
46.
Bogen  DL, Hanusa  BH, Baker  R, Medoff-Cooper  B, Cohlan  B.  Randomized clinical trial of standard- versus high-calorie formula for methadone-exposed infants: a feasibility study.  Hosp Pediatr. 2018;8(1):7-14. doi:10.1542/hpeds.2017-0114PubMedGoogle ScholarCrossref
47.
Raith  W, Schmölzer  GM, Resch  B,  et al.  Laser acupuncture for neonatal abstinence syndrome: a randomized controlled trial.  Pediatrics. 2015;136(5):876-884. doi:10.1542/peds.2015-0676PubMedGoogle ScholarCrossref
48.
Backes  CH, Backes  CR, Gardner  D, Nankervis  CA, Giannone  PJ, Cordero  L.  Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting.  J Perinatol. 2012;32(6):425-430. doi:10.1038/jp.2011.114PubMedGoogle ScholarCrossref
49.
Smirk  CL, Bowman  E, Doyle  LW, Kamlin  O.  Home-based detoxification for neonatal abstinence syndrome reduces length of hospital admission without prolonging treatment.  Acta Paediatr. 2014;103(6):601-604. doi:10.1111/apa.12603PubMedGoogle ScholarCrossref
50.
Kelly  LE, Knoppert  D, Roukema  H, Rieder  MJ, Koren  G.  Oral morphine weaning for neonatal abstinence syndrome at home compared with in-hospital: an observational cohort study.  Paediatr Drugs. 2015;17(2):151-157. doi:10.1007/s40272-014-0096-yPubMedGoogle ScholarCrossref
51.
Lee  J, Hulman  S, Musci  M  Jr, Stang  E.  Neonatal abstinence syndrome: influence of a combined inpatient/outpatient methadone treatment regimen on the average length of stay of a Medicaid NICU population.  Popul Health Manag. 2015;18(5):392-397. doi:10.1089/pop.2014.0134PubMedGoogle ScholarCrossref
52.
Loudin  S, Werthammer  J, Prunty  L, Murray  S, Shapiro  JI, Davies  TH.  A management strategy that reduces NICU admissions and decreases charges from the front line of the neonatal abstinence syndrome epidemic.  J Perinatol. 2017;37(10):1108-1111. doi:10.1038/jp.2017.101PubMedGoogle ScholarCrossref
53.
Hall  ES, Meinzen-Derr  J, Wexelblatt  SL.  Cohort analysis of a pharmacokinetic-modeled methadone weaning optimization for neonatal abstinence syndrome.  J Pediatr. 2015;167(6):1221. doi:10.1016/j.jpeds.2015.09.038PubMedGoogle ScholarCrossref
54.
Hall  ES, Wexelblatt  SL, Crowley  M,  et al; OCHNAS Consortium.  Implementation of a neonatal abstinence syndrome weaning protocol: a multicenter cohort study.  Pediatrics. 2015;136(4):e803-e810. doi:10.1542/peds.2015-1141PubMedGoogle ScholarCrossref
55.
Hodgson  ZG, Abrahams  RR.  A rooming-in program to mitigate the need to treat for opiate withdrawal in the newborn.  J Obstet Gynaecol Can. 2012;34(5):475-481.PubMedGoogle ScholarCrossref
56.
Brown  MS, Hayes  MJ, Thornton  LM.  Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial.  J Perinatol. 2015;35(4):278-283. doi:10.1038/jp.2014.194PubMedGoogle ScholarCrossref
57.
Nayeri  F, Sheikh  M, Kalani  M,  et al.  Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial.  BMC Pediatr. 2015;15:57. doi:10.1186/s12887-015-0377-9PubMedGoogle ScholarCrossref
58.
Young  ME, Hager  SJ, Spurlock  D.  Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome.  Am J Heal Pharm. 2015;72(23 suppl 3):S162-S167. doi:10.2146/sp150025Google ScholarCrossref
59.
Burke  S, Beckwith  AM. Morphine versus methadone treatment for neonatal withdrawal and impact on early infant development [published online July 25, 2017].  Glob Pediatr Heal. doi:10.1177/2333794X1772112Google Scholar
60.
Kraft  WK, Gibson  E, Dysart  K,  et al.  Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.  Pediatrics. 2008;122(3):e601-e607. doi:10.1542/peds.2008-0571PubMedGoogle ScholarCrossref
61.
Hall  ES, Isemann  BT, Wexelblatt  SL,  et al.  A cohort comparison of buprenorphine versus methadone treatment for neonatal abstinence syndrome.  J Pediatr. 2016;170:39-44. doi:10.1016/j.jpeds.2015.11.039PubMedGoogle ScholarCrossref
62.
Hall  ES, Rice  WR, Folger  AT, Wexelblatt  SL.  Comparison of neonatal abstinence syndrome treatment with sublingual buprenorphine versus conventional opioids.  Am J Perinatol. November 2017. doi:10.1055/s-0037-1608634PubMedGoogle Scholar
63.
Kraft  WK, Adeniyi-Jones  SC, Chervoneva  I,  et al.  Buprenorphine for the treatment of the neonatal abstinence syndrome.  N Engl J Med. 2017;376(24):2341-2348. doi:10.1056/NEJMoa1614835PubMedGoogle ScholarCrossref
64.
Agthe  AG, Kim  GR, Mathias  KB,  et al.  Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.  Pediatrics. 2009;123(5):e849-e856. doi:10.1542/peds.2008-0978PubMedGoogle ScholarCrossref
65.
Surran  B, Visintainer  P, Chamberlain  S, Kopcza  K, Shah  B, Singh  R.  Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome: a prospective randomized clinical trial.  J Perinatol. 2013;33(12):954-959. doi:10.1038/jp.2013.95PubMedGoogle ScholarCrossref
66.
Bada  HS, Sithisarn  T, Gibson  J,  et al.  Morphine versus clonidine for neonatal abstinence syndrome.  Pediatrics. 2015;135(2):e383-e391. doi:10.1542/peds.2014-2377PubMedGoogle ScholarCrossref
67.
Devlin  LA, Lau  T, Radmacher  PG.  Decreasing total medication exposure and length of stay while completing withdrawal for neonatal abstinence syndrome during the neonatal hospital stay.  Front Pediatr. 2017;5:216. doi:10.3389/fped.2017.00216PubMedGoogle ScholarCrossref
68.
Binder  T, Vavrinková  B.  Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department.  Neuro Endocrinol Lett. 2008;29(1):80-86.PubMedGoogle Scholar
69.
Bier  JB, Finger  AS, Bier  BA, Johnson  TA, Coyle  MG.  Growth and developmental outcome of infants with in-utero exposure to methadone vs buprenorphine.  J Perinatol. 2015;35(8):656-659. doi:10.1038/jp.2015.22PubMedGoogle ScholarCrossref
70.
Whitham  JN, Spurrier  NJ, Baghurst  PA, Weston  P, Sawyer  MG.  Visual evoked potential latencies of three-year-old children prenatally exposed to buprenorphine or methadone compared with non-opioid exposed children: the results of a longitudinal study.  Neurotoxicol Teratol. 2015;52(pt A):17-24. doi:10.1016/j.ntt.2015.09.008PubMedGoogle ScholarCrossref
71.
MacMillan  KDL, Rendon  CP, Verma  K, Riblet  N, Washer  DB, Volpe Holmes  A.  Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis  [published online February 5, 2018].  JAMA Pediatr. doi:10.1001/jamapediatrics.2017.5195PubMedGoogle Scholar
72.
Brogly  SB, Saia  KA, Walley  AY, Du  HM, Sebastiani  P.  Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.  Am J Epidemiol. 2014;180(7):673-686. doi:10.1093/aje/kwu190PubMedGoogle ScholarCrossref
73.
Reddy  UM, Davis  JM, Ren  Z, Greene  MF; Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers.  Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation.  Obstet Gynecol. 2017;130(1):10-28. doi:10.1097/AOG.0000000000002054PubMedGoogle ScholarCrossref
74.
Huybrechts  KF, Bateman  BT, Desai  RJ,  et al.  Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study.  BMJ. 2017;358:j3326.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements